title: Systemic administration of recombinant interferon alfa in carcinoma patients upregulates the expression of the carcinoma-associated antigens tumor-associated glycoprotein-72 and carcinoembryonic antigen.
abstract: OBJECTIVE
  The ability of interferons (IFNs) to enhance tumor-associated antigen expression may be an important approach to enhance the efficacy of some monoclonal antibody (MAb)-based protocols for tumor diagnosis and/or therapy. The present study was designed to determine whether systemic IFN alpha-2a administration (via the intramuscular [IM] route) could upregulate the expression of tumor-associated glycoprotein-72 (TAG-72) and/or carcinoembryonic antigen (CEA) at histologically confirmed sites of carcinoma.
  
  
  METHODS
  Eighteen patients diagnosed with gastrointestinal (GI) carcinoma received systemic IFN alpha-2a according to four dose schedules. In cohorts I and II, patients received two injections of 3 or 6 x 10(6) U IFN alpha-2a per injection, respectively. Patients in cohorts III and IV received the same doses of IFN alpha-2a, 3 and 6 x 10(6) U, respectively, but three injections were given. Tumor and normal colonic mucosa biopsies were obtained from each patient by endoscopy before IFN alpha-2a and after IFN alpha-2a at surgery. The levels of TAG-72 and CEA expression were measured by (1) immunohistochemistry and reported as percent antigen-positive tumor cells, as well as the relative staining intensity, and (2) a quantitative radioimmunoassay.
  
  
  RESULTS
  TAG-72 and CEA levels were consistently increased in tumor biopsies taken from patients in cohorts III and IV. For example, of 10 patients treated in cohorts III and IV, eight had enhanced TAG-72 expression when measured either as percentage TAG-72-positive tumor cells or as an increased MAb staining intensity following IFN alpha-2a. CEA expression in tumor biopsies from seven of 10 patients in cohorts III and IV was also elevated following IFN alpha-2a treatment. Quantitative analysis of TAG-72 and CEA levels in tumor biopsies confirmed higher tumor antigen levels following IFN alpha-2a administration. No such increases in TAG-72 or CEA levels were observed in tumor samples taken from patients in cohorts I and II. CEA or TAG-72 expression in samples of histologically confirmed normal colonic mucosa showed little or no change after IFN alpha-2a treatment.
  
  
  CONCLUSIONS
  Systemic IFN alpha-2a administration can upregulate TAG-72 and CEA expression at distal tumor sites, which may play an important role in immunodiagnosis and therapy.
authors.affiliation: Department of Surgery, University of Rome Tor Vergata, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Roselli
authors.forename: F
authors.initials: F
authors.lastname: Guadagni
authors.forename: O
authors.initials: O
authors.lastname: Buonomo
authors.forename: A
authors.initials: A
authors.lastname: Belardi
authors.forename: V
authors.initials: V
authors.lastname: Vittorini
authors.forename: R
authors.initials: R
authors.lastname: Mariani-Costantini
authors.forename: J W
authors.initials: JW
authors.lastname: Greiner
authors.forename: C U
authors.initials: CU
authors.lastname: Casciani
authors.forename: J
authors.initials: J
authors.lastname: Schlom
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology* / Q000628:therapy; D000951:Antigens, Neoplasm / Q000378:metabolism*; D002272:Carcinoembryonic Antigen / Q000378:metabolism*; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000276:immunology* / Q000628:therapy; D006023:Glycoproteins / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D007273:Injections, Intramuscular; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D011863:Radioimmunoassay; D011994:Recombinant Proteins; D015854:Up-Regulation
chemical_list: D000951:Antigens, Neoplasm; D002272:Carcinoembryonic Antigen; D006023:Glycoproteins; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; C047052:tumor-associated antigen 72